The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
Open accessAbstract
Summary Tumor-infiltrating CD8 T cells were found to frequently express the inhibitory receptor NKG2A, particularly in immune-reactive environments and after therapeutic cancer vaccination. High dimensional cluster analysis demonstrated that NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. To examine if NKG2A represented an adaptive resistance mechanism to cancer vaccination, we blocked the receptor with an antibody and knocked out its ligand Qa-1b, the conserved ortholog of HLA-E, in four mouse tumor models. The impact of therapeutic vaccines was greatly potentiated by disruption of the NKG2A/Qa-1b axis, even in a PD-1 refractory mouse model. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. These findings indicate that NKG2A-blocking antibodies might improve clinical responses to therapeutic cancer vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912217 · Cited by 6,566
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Comprehensive genomic characterization of head and neck squamous cell carcinomas
The Cancer Genome Atlas Network (2015) · Nature · doi:10.1038/nature14129 · Cited by 3,877
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,227
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,221
Self-citationHuman NK Cell Education by Inhibitory Receptors for MHC Class I
Anfossi, N., André, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.013 · Cited by 1,211
Self-citationPredicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Self-citationOverwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Self-citationOssendorp, F., Mengedé, E., Camps, M., Filius, R., & Melief, C. J. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.693 · Cited by 610
Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells
Hombrink, P., Helbig, C., Backer, R. A., Piet, B., Oja, A. E., Stark, R., Brasser, G., Jongejan, A., Jonkers, R. E., Nota, B., et al. (2016) · Nature Immunology · doi:10.1038/ni.3589 · Cited by 455
Webb, J. R., Milne, K., Watson, P., deLeeuw, R. J., & Nelson, B. H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1877 · Cited by 434
Snyder, C. M., Cho, K. S., Bonnett, E. L., van Dommelen, S., Shellam, G. R., & Hill, A. B. (2008) · Immunity · doi:10.1016/j.immuni.2008.07.017 · Cited by 302
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271
Precursors of human CD4 + cytotoxic T lymphocytes identified by single-cell transcriptome analysis
Patil, V. S., Madrigal, A., Schmiedel, B. J., Clarke, J., O’Rourke, P., de Silva, A. D., Harris, E., Peters, B., Seumois, G., Weiskopf, D., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aan8664 · Cited by 262
NKG2A Complexed with CD94 Defines a Novel Inhibitory Natural Killer Cell Receptor
Brooks, A. G., Posch, P. E., Scorzelli, C. J., Borrego, F., & Coligan, J. E. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.4.795 · Cited by 262
Le Dréan, E., Vély, F., Olcese, L., Cambiaggi, A., Guia, S., Krystal, G., Gervois, N., Moretta, A., Jotereau, F., & Vivier, E. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<264::aid-immu264>3.0.co;2-o · Cited by 254
Vance, R. E., Jamieson, A. M., & Raulet, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1801 · Cited by 238
Kaiser, B. K., Barahmand-pour, F., Paulsene, W., Medley, S., Geraghty, D. E., & Strong, R. K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2878 · Cited by 229
CD94-NKG2A receptors regulate antiviral CD8+ T cell responses
Moser, J. M., Gibbs, J., Jensen, P. E., & Lukacher, A. E. (2002) · Nature Immunology · doi:10.1038/ni757 · Cited by 220
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+T lymphocytes
Gooden, M., Lampen, M., Jordanova, E. S., Leffers, N., Trimbos, J. B., van der Burg, S. H., Nijman, H., & van Hall, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100354108 · Cited by 215
Self-citationStructural Features Impose Tight Peptide Binding Specificity in the Nonclassical MHC Molecule HLA-E
O'Callaghan, C. A., Tormo, J., Willcox, B. E., Braud, V. M., Jakobsen, B. K., Stuart, D. I., McMichael, A. J., Bell, J. I., & Jones, E. Y. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80053-2 · Cited by 205
CD74 and intratumoral immune response in breast cancer
Wang, Z.-Q., Milne, K., Webb, J. R., & Watson, P. H. (2017) · Oncotarget · doi:10.18632/oncotarget.8610 · Cited by 202
Bertone, S., Schiavetti, F., Bellomo, R. G., Vitale, C., Ponte, M., Moretta, L., & Mingari, M. C. (1999) · European Journal of Immunology · Cited by 181
Malmberg, K.-J., Levitsky, V., Norell, H., Matos, C. T. D., Carlsten, M., Schedvins, K., Rabbani, H., Moretta, A., Söderström, K., Levitskaya, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15564 · Cited by 180
CD103 and Intratumoral Immune Response in Breast Cancer
Wang, Z., Milne, K., Derocher, H., Webb, J. R., Nelson, B. H., & Watson, P. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0732 · Cited by 169
Komdeur, F. L., Prins, T. M., van de Wall, S., Plat, A., Wisman, G. B. A., Hollema, H., Daemen, T., Church, D. N., de Bruyn, M., & Nijman, H. W. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338230 · Cited by 168
Welters, M. J. P., Ma, W., Santegoets, S. J. A. M., Goedemans, R., Ehsan, I., Jordanova, E. S., van Ham, V. J., van Unen, V., Koning, F., van Egmond, S. I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2140 · Cited by 167
Self-citationMalmberg, K., Levitsky, V., Norell, H., de Matos, C. T., Carlsten, M., Schedvins, K., Rabbani, H., Moretta, A., Söderström, K., Levitskaya, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215564 · Cited by 151
Sheu, B., Chiou, S., Lin, H., Chow, S., Huang, S., Ho, H., & Hsu, S.-M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2108 · Cited by 141
Leavey, J. K., Vance, R. E., Pohl, J., Martin, A. M., Raulet, D. H., & Jensen, P. E. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.613 · Cited by 116
Kleinovink, J. W., van Driel, P. B., Snoeks, T. J. A., Prokopi, N., Fransen, M. F., Cruz, L. J., Mezzanotte, L., Chan, A. B., Löwik, C. W. G. M., & OSSENDORP, F. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0515 · Cited by 115
Heusinkveld, M., Goedemans, R., Briët, R. J. P., Gelderblom, H. A. J., Nortier, J. W. R., Gorter, A., Smit, V. T. H. B. M., Langeveld, A. P. M., Jansen, J. C., & van der Burg, S. H. (2011) · International Journal of Cancer · doi:10.1002/ijc.26497 · Cited by 105
Yazdi, M. T., van Riet, S., van Schadewijk, A. M., Fiocco, M. F., van Hall, T., Taube, C., Hiemstra, P. S., & van der Burg, S. H. (2015) · Oncotarget · doi:10.18632/oncotarget.6506 · Cited by 105
Piersma, S. J., Welters, M. J. P., van der Hulst, J. M., Kloth, J. N., Kwappenberg, K. M. C., Trimbos, B. J. B. M. Z., Melief, C. J. M., Hellebrekers, B. W. J., Fleuren, G. J., Kenter, G. G., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23162 · Cited by 87
Self-citationvan Steenwijk, P. J. D. V., Heusinkveld, M., Ramwadhdoebé, T. H., Löwik, M. J. G., van der Hulst, J. M., Goedemans, R., Piersma, S. J., Kenter, G. G., & van der Burg, S. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4299 · Cited by 85
Self-citationBösmüller, H.-C., Wagner, P., Peper-Gabriel, J. K., Schuster, H., Pham, D. L., Greif, K. F., Beschorner, C., Rammensee, H., Stevanović, S., Fend, F., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000672 · Cited by 85
van der Sluis, T. C., Sluijter, M., van Duikeren, S., West, B. L., Melief, C. J. M., Arens, R., van der Burg, S. H., & van Hall, T. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0052 · Cited by 84
Self-citationAndersson, E. K., Poschke, I. C., Villabona, L. E. E., Carlson, J. W., Lundqvist, A., Kiessling, R. W., Seliger, B., & Masucci, G. V. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052213 · Cited by 73
Expression of CD94–NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells
Braud, V. M., Aldemir, H., Bréart, B., & Ferlin, W. G. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00064-4 · Cited by 65
Zhou, J., Matsuoka, M., Cantor, H., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.25 · Cited by 55
Silva, T. G., Crispim, J. C. O., Miranda, F. A., Hassumi, M. K., de Mello, J. M. Y., Simões, R. T., Souto, F. J. D., Soares, E. G., Donadi, E. A., & Soares, C. P. (2011) · PubMed · doi:10.14670/hh-26.1487 · Cited by 53
Webb, J. R., Milne, K., & Nelson, B. H. (2014) · OncoImmunology · doi:10.4161/onci.27668 · Cited by 51
Ly, L. V., Sluijter, M., Versluis, M., Luyten, G. P. M., van der Burg, S. H., Melief, C. J. M., Jager, M. J., & van Hall, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2288 · Cited by 50
Self-citationvan Esch, E. M. G., Tummers, B., Baartmans, V., Osse, E. M., ter Haar, N. T., Trietsch, M. D., Hellebrekers, B. W. J., Holleboom, C. A. G., Nagel, H., Tan, L. T., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28713 · Cited by 46
Gunturi, A., Berg, R. E., Crossley, E. C., Murray, S. E., & Forman, J. (2005) · European Journal of Immunology · doi:10.1002/eji.200425735 · Cited by 45
Effective Cooperation of Monoclonal Antibody and Peptide Vaccine for the Treatment of Mouse Melanoma
Ly, L. V., Sluijter, M., van der Burg, S. H., Jager, M. J., & van Hall, T. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200135 · Cited by 30
Self-citationvan Esch, E. M. G., van Poelgeest, M. I. E., Kouwenberg, S., Osse, E. M., Trimbos, J. B., Fleuren, G. J., Jordanova, E. S., & van der Burg, S. H. (2014) · International Journal of Cancer · doi:10.1002/ijc.29174 · Cited by 28
Tissue-Protective Effects of NKG2A in Immune-Mediated Clearance of Virus Infection
Ely, K. H., Matsuoka, M., DeBerge, M., Ruby, J. A., Liu, J., Schneider, M. J., Wang, Y., Hahn, Y. S., & Enelow, R. I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108385 · Cited by 16
Cited by
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,221
Self-citationMelief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Self-citationHarnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling
Qian, J., Olbrecht, S., Boeckx, B., Vos, H., Laoui, D., Etlioglu, E., Wauters, E., Pomella, V., Verbandt, S., Busschaert, P., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0355-0 · Cited by 817
Metadata
- Authors
- van Montfoort, N., Borst, L., Korrer, M. J., Sluijter, M., Marijt, K. A., Santegoets, S. J., van Ham, V. J., Ehsan, I., Charoentong, P., André, P., Wagtmann, N., Welters, M. J. P., Kim, Y. J., Piersma, S. J., van der Burg, S. H., & van Hall, T.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 175
- Issue
- 7
- Pages
- 1744-1755.e15
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2903493397
- Cited by
- 333
- References
- 55
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.